Pozharitskaia M M, Kop'eva T N, Makarova O V, Shabanova M E
Ter Arkh. 1988;60(4):75-7.
A study of the clinical efficacy and the immunomodulating and antiinflammatory effect of ENCAD was conducted in 20 patients with Sjogren's disease (SD) of various degrees of activity of oral mucosa involvement and in a group of 23 healthy controls, with a saline solution as placebo. ENCAD was shown to lessen the expression of the clinical symptoms of xerostomia in both groups of a low and a moderate and high degrees of local activity of an inflammatory process. A tendency to the normalization of regeneration and desquamation in the oral mucosa epithelium was observed against a background of the reduction of an inflammatory reaction. ENCAD produced an immuno modulating effect lowering the blood level of theophylline-resistant and raising the level of theophylline-sensitive T-lymphocytes.
对20例口腔黏膜受累程度不同的干燥综合征（SD）患者以及23名健康对照者进行了一项关于ENCAD临床疗效、免疫调节和抗炎作用的研究，以生理盐水作为安慰剂。结果显示，在炎症过程低度、中度和高度局部活动的两组患者中，ENCAD均可减轻口干临床症状的表现。在炎症反应减轻的背景下，观察到口腔黏膜上皮再生和脱屑有趋于正常化的倾向。ENCAD产生了免疫调节作用，降低了茶碱抵抗性T淋巴细胞的血液水平，并提高了茶碱敏感性T淋巴细胞的水平。
